Get the Stockscreener App
1.09
3.54%
-0.04
After Hours:
1.12
0.03
+2.75%
Context Therapeutics Inc stock is traded at $1.09, with a volume of 216.91K.
It is down -3.54% in the last 24 hours and up +12.51% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.13
Open:
$1.13
24h Volume:
216.91K
Relative Volume:
0.76
Market Cap:
$97.78M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.1978
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-13.49%
1M Performance:
+12.51%
6M Performance:
+25.72%
1Y Performance:
-50.00%
1-Day Range:
$1.052
$1.15
1-Week Range:
$1.052
$1.34
52-Week Range:
$0.49
$2.3257
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.09 | 101.37M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Is Context Therapeutics Inc. a candidate for recovery playBond Market & Fast Entry and Exit Trade Plans - newser.com
Real time scanner hits for Context Therapeutics Inc. explained2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
Context Therapeutics Inc. stock trendline breakdown2025 Earnings Impact & Weekly High Potential Stock Alerts - newser.com
What’s the recovery path for long term holders of Context Therapeutics Inc.Trade Performance Summary & Precise Swing Trade Alerts - newser.com
Is Context Therapeutics Inc. stock positioned well for digital economyPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
What recovery options are there for Context Therapeutics Inc.Portfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Is Context Therapeutics Inc. stock resilient to inflationWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - newser.com
Context Therapeutics Grants Stock Options to New Hire - MSN
How to interpret RSI for Context Therapeutics Inc. stockM&A Rumor & Weekly High Conviction Ideas - newser.com
Does Context Therapeutics Inc. stock trade at a discount to peersPortfolio Return Summary & Safe Entry Zone Identification - newser.com
Applying chart zones and confluence areas to Context Therapeutics Inc.2025 Price Action Summary & Consistent Profit Focused Trading Strategies - newser.com
Is Context Therapeutics Inc. stock a defensive play in 2025July 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
Why hedge funds are buying Context Therapeutics Inc. stockEarnings Recap Summary & Precise Trade Entry Recommendations - newser.com
Exit strategy if you’re trapped in Context Therapeutics Inc.July 2025 EndofMonth & Comprehensive Market Scan Insights - newser.com
What drives Context Therapeutics Inc stock priceEnergy Sector Updates & Small Budget Trading Ideas - earlytimes.in
Context Therapeutics (CNTX) Projected to Post Earnings on Wednesday - MarketBeat
Statistical indicators supporting Context Therapeutics Inc.’s strengthTake Profit & Weekly High Potential Alerts - newser.com
Is Context Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Update & Fast Gain Stock Trading Tips - newser.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer - GlobeNewswire Inc.
Context Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Context Therapeutics (NASDAQ: CNTX) to join Guggenheim and Stifel investor conferences - Stock Titan
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):